Literature DB >> 12917755

Role of surveillance in intestinal metaplasia of the esophagus and gastroesophageal junction.

Guido N J Tytgat1, Johanna W Van Sandick, J Jan B van Lanschot, Huug Obertop.   

Abstract

This article reviews current concepts of cancer surveillance in esophageal columnar metaplasia (Barrett's esophagus) and intestinal metaplasia at the gastroesophageal junction. An overview is given of the available data on the prevalence of intestinal metaplasia in biopsies from the distal esophagus and from the gastroesophageal junction. Furthermore, special attention is given to the endoscopic detection of dysplasia and early malignancy. Finally, the costs of endoscopic surveillance and its effect on mortality rates from esophageal adenocarcinoma are discussed.

Entities:  

Mesh:

Year:  2003        PMID: 12917755     DOI: 10.1007/s00268-003-7194-2

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  47 in total

1.  Barrett's esophagus and adenocarcinoma of the esophagus and gastroesophageal junction.

Authors:  F G Duhaylongsod; W G Wolfe
Journal:  J Thorac Cardiovasc Surg       Date:  1991-07       Impact factor: 5.209

2.  Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions.

Authors:  B J Reid; W M Weinstein; K J Lewin; R C Haggitt; G VanDeventer; L DenBesten; C E Rubin
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

3.  Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion.

Authors:  S A McClave; H W Boyce; M R Gottfried
Journal:  Gastrointest Endosc       Date:  1987-12       Impact factor: 9.427

4.  Complications of gastroesophageal reflux disease. Role of the lower esophageal sphincter, esophageal acid and acid/alkaline exposure, and duodenogastric reflux.

Authors:  H J Stein; A P Barlow; T R DeMeester; R A Hinder
Journal:  Ann Surg       Date:  1992-07       Impact factor: 12.969

5.  Intestinal metaplasia of the gastric cardia.

Authors:  T G Morales; R E Sampliner; A Bhattacharyya
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

6.  Barrett's esophagus: development of dysplasia and adenocarcinoma.

Authors:  W Hameeteman; G N Tytgat; H J Houthoff; J G van den Tweel
Journal:  Gastroenterology       Date:  1989-05       Impact factor: 22.682

7.  Adenocarcinoma of the esophagogastric junction and Barrett's esophagus.

Authors:  A J Cameron; C T Lomboy; M Pera; H A Carpenter
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

Review 8.  Barrett's esophagus, dysplasia, and adenocarcinoma.

Authors:  R C Haggitt
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

9.  Histopathologic characteristics of early adenocarcinoma in Barrett's esophagus.

Authors:  T Nishimaki; A H Hölscher; M Schüler; E Bollschweiler; K Becker; J R Siewert
Journal:  Cancer       Date:  1991-10-15       Impact factor: 6.860

10.  The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.

Authors:  W Polkowski; J J van Lanschot; F J Ten Kate; J P Baak; G N Tytgat; H Obertop; W J Voorn; G J Offerhaus
Journal:  Surg Oncol       Date:  1995-06       Impact factor: 3.279

View more
  3 in total

1.  Prognostic value of body mass index on short-term and long-term outcome after resection of esophageal cancer.

Authors:  B A Grotenhuis; B P L Wijnhoven; G J Hötte; E P van der Stok; H W Tilanus; J J B van Lanschot
Journal:  World J Surg       Date:  2010-11       Impact factor: 3.352

2.  A labelled discrete choice experiment adds realism to the choices presented: preferences for surveillance tests for Barrett esophagus.

Authors:  Michelle E Kruijshaar; Marie-Louise Essink-Bot; Bas Donkers; Caspar W N Looman; Peter D Siersema; Ewout W Steyerberg
Journal:  BMC Med Res Methodol       Date:  2009-05-19       Impact factor: 4.615

3.  Different perceptions of the burden of upper GI endoscopy: an empirical study in three patient groups.

Authors:  Marie-Louise Essink-Bot; Michelle E Kruijshaar; Dirk J Bac; Pieter J Wismans; Frank ter Borg; Ewout W Steyerberg; Peter D Siersema
Journal:  Qual Life Res       Date:  2007-07-17       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.